PTS Diagnostics, Inc., a manufacturer of high-quality point-of-care diabetes-related blood testing devices, is announcing the planned closure of its Sunnyvale, CA, manufacturing facility. The closure process will begin on December 5, 2025, with final closure expected to be effective on or around March 31, 2026.

This move is being made to take advantage of manufacturing capacity resulting from the opening of the Whitestown facility in July 2019. This will allow the creation of production efficiencies resulting from consolidation of both their A1CNow^® and CardioChek^® product lines into one central manufacturing location.

PTS Diagnostics, Inc is eternally grateful to the Sunnyvale community where A1CNow manufacturing has taken place since January 2014.

“We express appreciation to all our employees. Their dedication and commitment to the production of A1CNow has positively impacted outcomes and quality of life for persons with diabetes in the global communities that we serve,” said Jonathan Chapman, President and CEO.

Please direct any questions related to the closure to Media Relations at 800-342-7226 ext. 3190.

About PTS Diagnostics

PTS Diagnostics is an innovative global point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company's name represents the three pillars upon which it has built its long-term success: People, Technology and Service. Headquartered in Whitestown, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. For more information, visit www.ptsdiagnostics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008341514/en/